Incyte's Customers Performance

Name: Incyte Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

INCY

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


INCY's Source of Revenues		During the corresponding time, Incyte Corporation recorded a revenue increase by 20.87 % year on year, sequentially revenue fell by -15.54 %. While revenue at the Incyte Corporation's corporate clients • List of INCY Customers

for the same period Incyte Corporation recorded revenue increase by 20.87 % year on year, sequentially revenue fell by -15.54 %.

• List of INCY Customers

Incyte's Business Units


Net sales	86.78 %	of total Revenue
JAKAFI	59.54 %	of total Revenue
OPZELURA	46.58 %	of total Revenue
ICLUSIG	5.49 %	of total Revenue
PEMAZYRE	3.61 %	of total Revenue
MINJUVI MONJUVI	3.87 %	of total Revenue
NIKTIMVO	9.07 %	of total Revenue
ZYNYZ	7.18 %	of total Revenue
Product royalty revenues	11.88 %	of total Revenue
JAKAVI Royalty	8.29 %	of total Revenue
OLUMIANT Royalty	2.84 %	of total Revenue
TABRECTA Royalty	0.47 %	of total Revenue
Other product royalty revenues	0.26 %	of total Revenue
Milestone and contract revenues	2.22 %	of total Revenue
Reportable Segment	100 %	of total Revenue
Net sales Reportable Segment	86.78 %	of total Revenue
Product royalty revenues Reportable Segment	11.88 %	of total Revenue
Milestone and contract revenues Reportable Segment	1.34 %	of total Revenue
United States	214.63 %	of total Revenue
Europe	15.52 %	of total Revenue
Other countries	1.38 %	of total Revenue
Product	203.72 %	of total Revenue
Royalty	25.61 %	of total Revenue
MINJUVI/MONJUVI	8.09 %	of total Revenue
Jakavi Royalty Revenues	18.05 %	of total Revenue
Olumiant Royalty Revenues	5.88 %	of total Revenue
Tabrecta Royalty Revenues	1 %	of total Revenue
Jakavi	18.05 %	of total Revenue
Tabrecta	1 %	of total Revenue
Olumiant	5.89 %	of total Revenue
Reportable	231.54 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Incyte's Comment on Sales, Marketing and Customers

News about Incyte Corporation Contracts

Incytes Hematology Breakthroughs to Take Center Stage at ASH 2025 Over 50 s Accepted,

Incyte Set to Shine at ASH Annual Meeting 2025 with Over 50 Accepted s Focused on Advancements in Hematology Incyte Corporation (Nasdaq: INCY), a leading biopharmaceutical company, has announced the acceptance of over 50 summaries (abstracts) for presentation at the Annual Meeting of the American Society of Hematology (ASH) set to be held from December 6 to 9, 2025, in Orlando, Florida. This impressive number not only highlights Incyte s commitment to advancing hematology and oncology but also underscores the continuing evolution of treatments for a variety of blood cancers.As the field of hematology progresses, the need for innovative and effective therapies has never been greater. Incyte s participation in...

Incyte to Present Groundbreaking Data on Ruxolitinib Cream at AAD 2025, Aiming to Transform Treatment for Prurigo N...

Wilmington, DE Incyte Corporation (Nasdaq: INCY) has announced its participation in the 2025 Annual Meeting of the American Academy of Dermatology (AAD), scheduled from March 7 to March 11 in Orlando, USA. The event promises to be a significant platform for the presentation of groundbreaking dermatological research and development efforts. Incyte will showcase several abstracts detailing new findings from its dermatology portfolio, with a special focus on Ruxolitinib cream (brand name Opzelura). Ruxolitinib cream has been at the forefront of innovative treatment solutions for various dermatological conditions, most notably Prurigo nodularis, a chronic skin disorder characterized by itchy, raised nodules.T...

Incyte Reports Early Clinical Success for CDK2 Inhibitor INCB123667 and Positive Results for Tafasitamab in Oncology ...

Promising Developments in Oncological Therapies: Incyte s CDK2 Inhibitor Shows Early Clinical Activity WILMINGTON, Del. Incyte Corporation (Nasdaq: INCY) has announced promising early clinical data for its CDK2 inhibitor, INCB123667, aimed at patients with advanced solid tumors, particularly ovarian cancer. CDK2 inhibitors are a class of drugs targeting cyclin-dependent kinase 2, an essential protein involved in cell division and cancer progression.The new findings are part of a broader initiative by Incyte to enhance its oncology pipeline, including recent advances in monoclonal antibody therapies. The company revealed that it would present key data at the upcoming European Society for Medical Oncology (...

Incyte to Unveil Significant Oncology Data at ESMO 2024,

Wilmington, Delaware, October 2023 Incyte Corporation (Nasdaq: INCY) has announced its intention to present significant findings f...

INCY's Stock Performance relative to it's Customers

INCY's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Incyte Corporation	25,334.61	5,361.02	1,431.78	2,844
SUBTOTAL	0.00	0.00	0.00	-

Sources: Incyte Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Incyte Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Incyte Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.